Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes

In brief

RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00064376

Run by

Cedars-Sinai Medical Center

Starts

2003-05-01

Expected to finish

2005-11-01

Last updated by the study team

2018-01-29

Who can join

Age: 25 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.